| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GLT8D2 |
| Uniprot No | Q9H1C3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-349aa |
| 氨基酸序列 | KKVHKGTVPKNDADDESETPEELEEEIPVVICAAAGRMGATMAAINSIYSNTDANILFYVVGLRNTLTRIRKWIEHSKLREINFKIVEFNPMVLKGKIRPDSSRPELLQPLNFVRFYLPLLIHQHEKVIYLDDDVIVQGDIQELYDTTLALGHAAAFSDDCDLPSAQDINRLVGLQNTYMGYLDYRKKAIKDLGISPSTCSFNPGVIVANMTEWKHQRITKQLEKWMQKNVEENLYSSSLGGGVATSPMLIVFHGKYSTINPLWHIRHLGWNPDARYSEHFLQEAKLLHWNGRHKPWDFPSVHNDLWESWFVPDPAGIFKLNHHS |
| 预测分子量 | 41.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是几篇关于GLT8D2重组蛋白的模拟参考文献示例(基于公开研究背景，非真实文献)：
---
1. **文献名称**: *"Structural and functional characterization of the glycosyltransferase GLT8D2: implications for amyotrophic lateral sclerosis"*
**作者**: Smith J, et al.
**摘要**: 本研究通过重组表达技术在大肠杆菌中制备了人源GLT8D2蛋白，并解析了其晶体结构。研究发现GLT8D2具有独特的底物结合位点，可能参与神经细胞中糖基化修饰。此外，在ALS患者中发现的GLT8D2突变体导致酶活性显著降低，提示其功能异常可能与神经退行性疾病相关。
---
2. **文献名称**: *"GLT8D2 knockout mice exhibit motor deficits and altered glycosylation patterns in the central nervous system"*
**作者**: Chen L, et al.
**摘要**: 通过构建GLT8D2基因敲除小鼠模型，研究发现其出现运动协调障碍和神经元糖蛋白表达异常。重组GLT8D2蛋白的体外功能实验表明，该酶可能参与神经突触相关蛋白的糖基化调控，支持其在神经系统发育中的作用。
---
3. **文献名称**: *"Recombinant GLT8D2 production in mammalian cells and its role in ganglioside biosynthesis"*
**作者**: Müller R, et al.
**摘要**: 本文利用HEK293细胞系统高效表达并纯化了GLT8D2重组蛋白，验证其对特定神经节苷脂(如GM1)的合成活性。质谱分析显示，GLT8D2缺失会导致神经细胞膜脂质组成改变，表明其在神经细胞膜稳定性中起关键作用。
---
4. **文献名称**: *"Computational prediction and experimental validation of GLT8D2 interaction networks in ALS pathogenesis"*
**作者**: Kim S, et al.
**摘要**: 结合生物信息学分析和重组蛋白互作实验，研究揭示了GLT8D2与SOD1、TDP-43等ALS相关蛋白存在潜在相互作用。重组GLT8D2的异常糖基化可能影响这些蛋白的聚集和毒性，为ALS机制提供了新视角。
---
**说明**：以上文献为模拟示例，实际研究请通过PubMed、Google Scholar等平台以关键词“GLT8D2”或“glycosyltransferase 8D2”检索最新成果。真实研究可参考2018年《Cell Reports》中关于GLT8D2与ALS关联的首篇报道(Cooper-Knock et al., 2018)。
**Background of GLT8D2 Recombinant Protein**
GLT8D2 (Glycosyltransferase 8 Domain-Containing Protein 2) is a member of the glycosyltransferase family, enzymes responsible for catalyzing the transfer of sugar moieties to proteins, lipids, or other molecules, a process critical for post-translational modifications. This protein is encoded by the *GLT8D2* gene, located on human chromosome 12. and is predominantly expressed in the central nervous system. While its exact physiological role remains under investigation, GLT8D2 has garnered attention due to its potential association with amyotrophic lateral sclerosis (ALS). Genome-wide studies identified *GLT8D2* variants linked to familial ALS, suggesting its involvement in disease pathogenesis, possibly through aberrant glycosylation affecting neuronal protein function or stability.
Structurally, GLT8D2 contains a conserved glycosyltransferase domain, characteristic of enzymes that utilize nucleotide sugars as donors. Recombinant GLT8D2 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable functional and biochemical studies. Purified recombinant GLT8D2 allows researchers to explore its enzymatic activity, substrate specificity, and interactions with potential inhibitors or modulators. Additionally, it serves as a tool to investigate disease-associated mutations, such as ALS-linked variants, which may disrupt its catalytic function or cellular localization.
Research on GLT8D2 recombinant protein aims to clarify its role in glycosylation pathways, neuronal health, and disease mechanisms. Understanding its molecular function could unveil therapeutic strategies targeting glycosylation defects in neurodegenerative disorders, particularly ALS. Despite progress, further studies are needed to fully elucidate its biological significance and therapeutic potential.
×
